Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25Â years of follow-up data

This study confirms that dyslipidemia is a common and long-lasting phenomenon among both allogeneic and autologous HSCT patients. Statins are effective, generally well-tolerated and should be highly recommended for the management of post-HSCT dyslipidemia.